203 related articles for article (PubMed ID: 29178442)
21. Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants.
Wu J; Gießmann T; Lang B; Elgadi M; Huang F
J Pharm Pharmacol; 2016 Apr; 68(4):459-66. PubMed ID: 27019158
[TBL] [Abstract][Full Text] [Related]
22. Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin.
Harvey RD; Aransay NR; Isambert N; Lee JS; Arkenau T; Vansteenkiste J; Dickinson PA; Bui K; Weilert D; So K; Thomas K; Vishwanathan K
Br J Clin Pharmacol; 2018 Dec; 84(12):2877-2888. PubMed ID: 30171779
[TBL] [Abstract][Full Text] [Related]
23. Osimertinib in a patient with non-small cell lung cancer and renal failure undergoing hemodialysis: a case report.
Matsunashi A; Fujimoto D; Hosoya K; Irie K; Fukushima S; Tomii K
Invest New Drugs; 2020 Aug; 38(4):1192-1195. PubMed ID: 31486987
[TBL] [Abstract][Full Text] [Related]
24. Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects.
Groenendaal-van de Meent D; den Adel M; van Dijk J; Barroso-Fernandez B; El Galta R; Golor G; Schaddelee M
Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):685-692. PubMed ID: 29752643
[TBL] [Abstract][Full Text] [Related]
25. Effect of food on the pharmacokinetics of clozapine orally disintegrating tablet 12.5 mg: a randomized, open-label, crossover study in healthy male subjects.
Disanto AR; Golden G
Clin Drug Investig; 2009; 29(8):539-49. PubMed ID: 19591515
[TBL] [Abstract][Full Text] [Related]
26. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
Odogwu L; Mathieu L; Goldberg KB; Blumenthal GM; Larkins E; Fiero MH; Rodriguez L; Bijwaard K; Lee EY; Philip R; Fan I; Donoghue M; Keegan P; McKee A; Pazdur R
Oncologist; 2018 Mar; 23(3):353-359. PubMed ID: 29242281
[TBL] [Abstract][Full Text] [Related]
27. Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects.
Small DS; Royalty J; Cannady EA; Hale C; Wang MD; Downs D; Suico JG
Pharmacotherapy; 2016 Jul; 36(7):749-56. PubMed ID: 27284735
[TBL] [Abstract][Full Text] [Related]
28. The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects.
Cao B; Ma T; Zhang Y; Huang L; Lin H; Jiang H; Zhao Y; Geng Y; Yang Y; Cao S; Li J
Invest New Drugs; 2024 Jun; 42(3):289-298. PubMed ID: 38602625
[TBL] [Abstract][Full Text] [Related]
29. Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.
Hsyu PH; Pignataro DS; Matschke K
Eur J Clin Pharmacol; 2017 Jan; 73(1):49-56. PubMed ID: 27718000
[TBL] [Abstract][Full Text] [Related]
30. Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility.
Ware JA; Dalziel G; Jin JY; Pellett JD; Smelick GS; West DA; Salphati L; Ding X; Sutton R; Fridyland J; Dresser MJ; Morrisson G; Holden SN
Mol Pharm; 2013 Nov; 10(11):4074-81. PubMed ID: 24099279
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P
Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795
[TBL] [Abstract][Full Text] [Related]
32. A Phase I, Randomized, Crossover, Open-label Study of the Pharmacokinetics of Solriamfetol (JZP-110) in Healthy Adult Subjects With and Without Food.
Zomorodi K; Kankam M; Lu Y
Clin Ther; 2019 Feb; 41(2):196-204. PubMed ID: 30598342
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole.
Offman E; Schobelock MJ; Brickl R; VanderMaelen CP; Ehrlich J; Eisert W
Am J Cardiovasc Drugs; 2013 Apr; 13(2):113-20. PubMed ID: 23532686
[TBL] [Abstract][Full Text] [Related]
34. Phase I study to evaluate of the gastric pH-dependent drug interaction between famitinib and the proton pump inhibitor omeprazole in healthy subjects.
Hu L; Cai M; Qian W; Dou T; Sun Q; Tang L; Wang H
Invest New Drugs; 2022 Dec; 40(6):1274-1281. PubMed ID: 36087164
[TBL] [Abstract][Full Text] [Related]
35. Impact of Disease and Treatment Response in Drug-Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non-Small Cell Lung Cancer.
Vishwanathan K; Cantarini M; So K; Masson E; Fetterolf J; Ramalingam SS; Harvey RD
Clin Transl Sci; 2020 Jan; 13(1):41-46. PubMed ID: 31498564
[TBL] [Abstract][Full Text] [Related]
36. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D
Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396
[TBL] [Abstract][Full Text] [Related]
37. Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.
Yu HA; Schoenfeld AJ; Makhnin A; Kim R; Rizvi H; Tsui D; Falcon C; Houck-Loomis B; Meng F; Yang JL; Tobi Y; Heller G; Ahn L; Hayes SA; Young RJ; Arcila ME; Berger M; Chaft JE; Ladanyi M; Riely GJ; Kris MG
JAMA Oncol; 2020 Jul; 6(7):1048-1054. PubMed ID: 32463456
[TBL] [Abstract][Full Text] [Related]
38. Absolute Bioavailability of Osimertinib in Healthy Adults.
Vishwanathan K; So K; Thomas K; Bramley A; English S; Collier J
Clin Pharmacol Drug Dev; 2019 Feb; 8(2):198-207. PubMed ID: 29683562
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
Akamatsu H; Toi Y; Hayashi H; Fujimoto D; Tachihara M; Furuya N; Otani S; Shimizu J; Katakami N; Azuma K; Miura N; Nishino K; Hara S; Teraoka S; Morita S; Nakagawa K; Yamamoto N
JAMA Oncol; 2021 Mar; 7(3):386-394. PubMed ID: 33410885
[TBL] [Abstract][Full Text] [Related]
40. A phase 1 randomized study evaluating the effect of omeprazole on the pharmacokinetics of a novel 5-hydroxytryptamine receptor 4 agonist, revexepride (SSP-002358), in healthy adults.
Pierce D; Corcoran M; Velinova M; Hossack S; Hoppenbrouwers M; Martin P
Drug Des Devel Ther; 2015; 9():1257-68. PubMed ID: 25767373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
